Press Releases Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
6.18 ^USD	+0.16%		-0.64%	+22.38%

May. 15	Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target	MT
May. 09	Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference	May. 30	GL
Wave Life Sciences : Improving the Potency and Sequence Versatility of RNA Editing Through Oligonucleotide Chemical Modifications	May. 24	PU
Wave Life Sciences : Impact of Phosphoryl Guanidine (PN) Variants on siRNA Potency and Durability in Hepatic and Extrahepatic Tissues	May. 24	PU
First clinical evidence for myocyte stem (satellite) cell targeting in DMD: Results from Part A of a Phase 1b/2 study of WVE-N531	May. 24	PU
A Phase 1b/2 Open label Study of WVE N531 in Patients with Duchenne Muscular Dystrophy: Part B (FORWARD 53) Study Design and Rationale	May. 24	PU
Wave Life Sciences : Potent, Durable mRNA Knockdown in Extrahepatic Tissues Using siRNAs With Novel Phosphoryl Guanidine Backbone Variants	May. 10	PU
Wave Life Sciences : Chemical Design of Oligonucleotides That Support Targeted RNA Editing in the CNS of Non-Human Primates	May. 09	PU
Wave Life Sciences: Q1 Earnings Snapshot	May. 09	AQ
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update	May. 09	GL
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer	May. 09	GL
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference	May. 07	GL
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024	May. 02	GL
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)	Apr. 30	GL
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	Apr. 23	GL
Wave Life Sciences to Present at Upcoming Investor Conferences	Mar. 27	GL
Wave Life Sciences: Q4 Earnings Snapshot	Mar. 06	AQ
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 06	GL
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024	Feb. 28	GL
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy	Feb. 27	GL
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones	Jan. 08	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Press Releases

Filters